Active Stocks
Thu Apr 18 2024 15:59:07
  1. Tata Steel share price
  2. 160.00 -0.03%
  1. Power Grid Corporation Of India share price
  2. 280.20 2.13%
  1. NTPC share price
  2. 351.40 -2.19%
  1. Infosys share price
  2. 1,420.55 0.41%
  1. Wipro share price
  2. 444.30 -0.96%
Business News/ Companies / News/  Roche dissolves Applied Science unit as it ends IBM alliance
BackBack

Roche dissolves Applied Science unit as it ends IBM alliance

Drugmaker says two types of products the unit sells will become part of its Molecular Diagnostics unit

Roche said on Tuesday it had ended its partnership with IBM for the development of a nanopore-based sequencing platform, due to high technical risks involved. (Roche said on Tuesday it had ended its partnership with IBM for the development of a nanopore-based sequencing platform, due to high technical risks involved.)Premium
Roche said on Tuesday it had ended its partnership with IBM for the development of a nanopore-based sequencing platform, due to high technical risks involved.
(Roche said on Tuesday it had ended its partnership with IBM for the development of a nanopore-based sequencing platform, due to high technical risks involved.)

Geneva: Roche Holding AG will dissolve its Applied Science laboratory supply business because of cuts in research funding and price pressure, affecting 170 jobs and ending an alliance with International Business Machines Corp.

Roche said two types of products the unit sells to scientists working with samples of genetic material will become part of its Molecular Diagnostics unit. Roche’s custom biotechnology portfolio will join the Professional Diagnostics business, while the company will create a unit to focus solely on gene sequencing, the drugmaker said in a statement on Tuesday.

Roche may be reacting to its competitors Life Technologies Corp., acquired by Thermo Fisher Scientific Inc., and Illumina Inc. having developed faster, cheaper ways to sequence genes, said Fabian Wenner, a Zurich-based analyst for Kepler Capital Markets. The Basel, Switzerland-based maker of drugs and medical technology abandoned a hostile takeover bid for Illumina over the US sequencing company’s price demands.

“The latest changes are a defensive move, and the acquisition would have been defensive as well," Wenner said in a telephone interview on Tuesday. He has a buy rating on Roche’s shares.

The reorganization will affect 110 jobs in Penzberg, Germany and 60 in Branford, Connecticut, Roche said, adding its outlook for 2013 remains unchanged.

Roche shares rose 1% in Zurich at 10:30 am local time, giving the drugmaker a market value of 196 billion Swiss francs ($209 billion).

Roche and IBM agreed in July 2010 to try to make genome sequencing for medical purposes cheaper and more common. The drugmaker said on Tuesday it had ended its partnership with IBM for the development of a nanopore-based sequencing platform, due to high technical risks involved. Bloomberg

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 23 Apr 2013, 08:49 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App